This blend is studied in receptor models involving GHRH and growth-hormone secretagogue signaling, ligand interaction, and pathway crosstalk.
- GHRH receptor signaling
- GHSR receptor signaling
- Receptor-pathway crosstalk
GHRH and GHSR are both on the label
A paper that used only Ipamorelin does not document the CJC-1295 sequence in this vial. A paper that used only a GHRH analog does not document the Ipamorelin half of the blend.
Tesamorelin is a different GHRH-analog listing, at $94.99, with task 134410.
Two masses, no single score
Task 121834 is the analytical record. There is no purity percent to quote.
This page is laboratory education for adults 21 and older. It is not a dosing guide, a treatment plan, or a ranking of which material to use. Not for human or veterinary use.
CJC-1295 (No DAC) 5 mg + Ipamorelin 5 mg research questions
What pathways are filed here?
GHRH receptor signaling, GHSR receptor signaling, and pathway crosstalk.
Does this replace tesamorelin?
No. Tesamorelin is a separate product and a separate report.
References and further reading
- PubMed literature index — CJC-1295 (No DAC) 5 mg + Ipamorelin 5 mg ↗
A continuously updated index of peer-reviewed biomedical literature. Study quality, model, and relevance must be assessed individually.
- FDA — Analytical Procedures and Methods Validation ↗
Regulatory guidance on analytical method development and validation.
- ICH Q2(R2) — Validation of Analytical Procedures ↗
International guidance on specificity, accuracy, precision, range, and robustness.
- Hoofnagle et al. — Recommendations for peptide storage and handling ↗
Peer-reviewed recommendations for peptide handling in quantitative laboratory workflows.
External links are provided for independent literature review. A link does not imply that every indexed paper supports the same conclusion or that findings apply beyond the model and conditions studied.